| |
Develop a commercial value creation story to differentiate your product and attract investors by leveraging our deep commercialization experience. Download the guide now.
|
|
Today’s Big NewsJun 13, 2025 |
|
In a capital-constrained environment, equipment financing offers a smart and flexible path forward. NFS Capital is here to help you keep innovating without waiting for your next funding round. Request more information.
|
|
| By James Waldron AstraZeneca has returned to recent collaborator CSPC Pharmaceuticals with $110 million in upfront cash to start work on finding new oral drugs for a range of chronic diseases. |
|
|
|
By Darren Incorvaia Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when deciding on a new tactical leader. The Big Pharma has hired physician-turned-analyst Chris Shibutani, M.D., as executive vice president and chief strategy officer, BMS announced on June 9. |
By James Waldron Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. |
Sponsored by WCG When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from trusted industry experts. |
By Gabrielle Masson Wegovy-maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early next year. |
Sponsored by Invest Puerto Rico Global trade uncertainty and evolving tariff policies are shifting how bioscience companies view their supply chains. |
By Darren Incorvaia,Zoey Becker After 25 years developing vaccines with French drugmaker Sanofi, Sanjay Gurunathan, M.D., has departed for GSK. Gurunathan will head up the British Big Pharma’s vaccine and infectious disease R&D from Boston, working under Chief Scientific Officer Tony Wood, Ph.D. |
By Gabrielle Masson After dropping its only clinical-stage candidate last month, ADC Therapeutics is shutting down a U.K. R&D site and laying off 30% of its workforce. |
By James Waldron Astellas Pharma will be inviting Japanese biotech startups to use its R&D lab as part of a government-backed acceleration program to help these companies “go global.” |
By Kevin Dunleavy For the second time in nine months, a Delaware judge has sided with Syntimmune shareholders over AstraZeneca, granting a $181 million award. The decision comes on top of a $130 million judgment issued in September of last year. |
By Paige Minemyer As the fight in the Senate over the "big beautiful bill" heats up, key Democrats have unveiled their own take on addressing fraud and waste in Medicaid. |
By Zoey Becker Zusduri is the first approved therapy for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), standing to replace the current surgical standard-of-care. |
By Ayla Ellison,Conor Hale,Heather Landi This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare. |
By Angus Liu Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. Otsuka detailed its phase 3 data in the kidney disease IgAN. Novartis is pressing for a speedy ruling in its Entresto patent litigation against MSN Pharmaceuticals. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare. |
|
|---|
|
|
|
From gene therapy pipelines to early-stage VC deals, biotech leaders are seeking clarity in the chaos. That’s why companies are sharing their insights through Fierce content hubs — with weekly features right here in your inbox. See how others are shaping the narrative.
|
|
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
